secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001171843-25-002427
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KPMG not standing for re-appointment as Aptose auditor; material weakness disclosed
--------------------------------------------------------------------------------

- KPMG informed Aptose on April 15, 2025 it will not stand for re-appointment for the 2025 annual audit.
- No disagreements on accounting principles or practices between KPMG and Aptose during fiscal years 2024/2023 and through April 15, 2025.
- KPMG identified a material weakness in internal control over financial reporting for complex financial instruments (warrants) as per 2024 10-K.
- Company has initiated process to appoint a new independent registered public accounting firm; KPMG authorized to respond to successor.
- KPMG issued unqualified reports on 2024 and 2023 financial statements; no internal control report due to smaller reporting company status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002427/0001171843-25-002427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002427/f8k_042325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer